Fisher & Paykel Healthcare has increased full year guidance based on a weaker currency.
FY20, which ends 31 March, is expected to see revenue of NZ$1.24b while NPAT should be between NZ$275-280m. That's a 30% lift from last year and a 5% lift from prior guidance.
As a manufacturer of hospital respiratory care products (~60% of revenues), and the massive ramp up in demand for such things things due to coronavirus, the coming year is likely to be a very strong one too.
Guidance gives an FY20 EPS of 48.2c, which puts shares on a PE of ~54 (at current price of $25.98)